Promethera: Liver Supply

Promethera: hepatic stem cells for liver genetic disorders and toxicology testing

A consistent shortage of human livers has limited the availability of the organs for transplantation and the ability for biomedical researchers to have a steady supply of hepatocytes for preclinical testing. Promethera Biosciences S.A. believes its human adult liver-derived mesenchymal stem cells can help solve both issues.

The company is developing the cells as a therapy for liver-related genetic disorders, and as a source of hepatocytes for preclinical metabolism and toxicology testing.

According to CEO Eric Halioua, more than 200 genetic disorders affect the liver, including

Read the full 848 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE